{"result": "(\"entity\"<|>KETOCONAZOL<|>ORGANIZATION<|>Ketoconazol is a medication used to treat Cushing's syndrome by inhibiting steroidogenesis, but it has hepatotoxicity as a significant side effect.)\n##\n(\"entity\"<|>MITOTANO<|>ORGANIZATION<|>Mitotano is a medication used in the treatment of Cushing's syndrome, known for its neurotoxic effects.)\n##\n(\"entity\"<|>METOPIRONA<|>ORGANIZATION<|>Metopirona is a medication that inhibits 11-β-hydroxylase and is used in the treatment of Cushing's syndrome.)\n##\n(\"entity\"<|>PASIREOTIDA<|>ORGANIZATION<|>Pasireotida is a medication used in the treatment of Cushing's syndrome, which can cause hypoglycemia as a side effect.)\n##\n(\"entity\"<|>UPTODATE<|>ORGANIZATION<|>UpToDate is a clinical decision support resource that provides evidence-based information on various medical topics, including Cushing's syndrome.)\n##\n(\"relationship\"<|>KETOCONAZOL<|>CUSHING'S SYNDROME<|>Ketoconazol is used to treat Cushing's syndrome by inhibiting cortisol synthesis<|>7)\n##\n(\"relationship\"<|>MITOTANO<|>CUSHING'S SYNDROME<|>Mitotano is used to treat Cushing's syndrome but has neurotoxic side effects<|>7)\n##\n(\"relationship\"<|>METOPIRONA<|>CUSHING'S SYNDROME<|>Metopirona is used to treat Cushing's syndrome by inhibiting cortisol production<|>7)\n##\n(\"relationship\"<|>PASIREOTIDA<|>CUSHING'S SYNDROME<|>Pasireotida is used to treat Cushing's syndrome and can cause hypoglycemia<|>7)\n##\n(\"relationship\"<|>UPTODATE<|>CUSHING'S SYNDROME<|>UpToDate provides information and guidelines on the diagnosis and treatment of Cushing's syndrome<|>8)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: suprarrenal. En: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscazo J, eds. Harrison\n          Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100:2807-31.                                                            Principios de Medicina Interna. 19.ª edición en español. México DF: Mc Graw Hill; 2016. p. 2309-29.\n        • Nieman LK, Biller BMK, Findiling JW, Newel-Price J, Savage MO, Steward PM, et al. The diagnosis of Cushing’s syndrome:                   • Estrada J, Abad A, Aller J. Síndrome de Cushing. Manual de Endocrinología y Nutrición. Disponible en: https://manual.seen.es\n          an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526-40.                                                (última modificación: 25 de noviembre de 2015).\n        • Steward PM, Newell-Price JDC. The adrenal cortex. En: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. Williams Textbook            • Nieman LK. Epidemiology and clinical manifestations of Cushing’s syndrome. UpToDate. Waltham, MA: UpToDate Inc. https://www.\n          of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016. p. 490-555.                                                                       uptodate.com. Literature review current through: Apr. 2019.\n                                                                                                                                                   • Nieman LK. Establishing the diagnosis of Cushing’s syndrome. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com.\n                                                                                                                                                     Literature review current through: Apr. 2019.\n                                                                                                                                                   • Nieman LK. Overview of the treatment of Cushing’s syndrome. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com.\n                                                                                                                                                     Literature review current through: Apr. 2019.\n     7  ¿Cuál de los siguientes no es un efecto adverso del tratamiento médico                                                                     • Nieman LK, Biller BMK, Findiling JW, Murad MH, Newel-Price J, Savage MO, et al. Treatment of Cushing’s syndrome:\n        del síndrome de Cushing?                                                                                                                     an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100:2807-31.\n                                                                                                                                                   • Nieman LK, Biller BMK, Findiling JW, Newel-Price J, Savage MO, Steward PM, et al. The diagnosis of Cushing’s syndrome:\n                                                                                                                                                     an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526-40.\n        A.   La toxicidad hepática con el ketoconazol.                                                                                             • Steward PM, Newell-Price JDC. The adrenal cortex. En: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. Williams Textbook\n        B.   La neurotoxicidad con el mitotano.                                                                                                      of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016. p. 490-555.\n        C.   Las náuseas con la metopirona.\n        D.   La hipoglucemia con la pasireotida.                                                                                                8  ¿Cuál de las siguientes afirmaciones                        es cierta en        relación con el diagnóstico\n                                                                                                                                                   del síndrome de Cushing?\n        COMENTARIO                                                                                                                                 A.  La utilización de contraste en la RMN de hipófisis no es relevante para el diagnóstico\n        Diversos fármacos que actúan directamente en las suprarrenales, inhibiendo la síntesis de                                                      de un microadenoma productor de ACTH.\n        cortisol, tienen un papel importante en el tratamiento de la enfermedad de Cushing porque                                                  B.  La existencia de una alcalosis hipopotasémica orienta hacia el diagnóstico de síndrome\n        son mucho más            efectivos que aquellos            que inhiben la        secreción hipofisaria de ACTH.                                de Cushing por ACTH ectópica.\n        El  ketoconazol,        que    inhibe varias       enzimas       de   la  esteroidogénesis, es            el más     utilizado.    La      C.  La gammagrafía suprarrenal es una prueba realizada habitualmente para el diagnóstico\n        hepatotoxicidad es su efecto adverso más importante, con elevación discreta de las transa-                                                     etiológico.\n        minasas en un 5-15% de los pacientes y fallo hepático                             grave en casos muy raros.                                D.  En la interpretación de los resultados obtenidos en el cateterismo de senos petrosos inferiores,\n        La metopirona actúa fundamentalmente inhibiendo la 11-β-hidroxilasa y consiguiendo una                                                         la valoración simultánea del gradiente de prolactina petroso-periférico no es de utilidad.\n        disminución rápida de los niveles de cortisol. Con frecuencia se observa un fenómeno de\n        escape que obliga a subir la dosis. Sus efectos secundarios más frecuentes\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>NIEMAN LK<|>PERSON<|>Nieman LK is a medical professional involved in the diagnosis and treatment of Cushing's syndrome, contributing to various clinical practice guidelines.)\n##\n(\"entity\"<|>BILLER BMK<|>PERSON<|>Biller BMK is a medical professional who co-authored clinical practice guidelines related to Cushing's syndrome.)\n##\n(\"entity\"<|>FINDILING JW<|>PERSON<|>Findiling JW is a medical professional who has contributed to the clinical practice guidelines for diagnosing and treating Cushing's syndrome.)\n##\n(\"entity\"<|>NEWEL-PRICE J<|>PERSON<|>Newel-Price J is a medical professional involved in the clinical guidelines for Cushing's syndrome.)\n##\n(\"entity\"<|>SAVAGE MO<|>PERSON<|>Savage MO is a medical professional who has contributed to the clinical practice guidelines for Cushing's syndrome.)\n##\n(\"entity\"<|>STEWARD PM<|>PERSON<|>Steward PM is a medical professional who has co-authored clinical practice guidelines regarding Cushing's syndrome.)\n##\n(\"entity\"<|>UPTODATE INC<|>ORGANIZATION<|>UpToDate Inc. is a medical information resource that provides literature reviews and guidelines on various medical conditions, including Cushing's syndrome.)\n##\n(\"entity\"<|>HARRISON SOCIETY<|>ORGANIZATION<|>The Harrison Society is an organization that publishes clinical practice guidelines in the field of medicine, including those for Cushing's syndrome.)\n##\n(\"entity\"<|>CLINICAL PRACTICE GUIDELINE<|>EVENT<|>Clinical practice guidelines are systematic recommendations developed to assist healthcare professionals in making decisions about appropriate healthcare for specific clinical circumstances, including Cushing's syndrome.)\n##\n(\"entity\"<|>CUSHING'S SYNDROME<|>EVENT<|>Cushing's syndrome is a hormonal disorder caused by prolonged exposure to high levels of cortisol, which is addressed in various clinical practice guidelines.)\n##\n(\"relationship\"<|>NIEMAN LK<|>UPTODATE INC<|>Nieman LK has contributed to the UpToDate Inc. literature reviews on Cushing's syndrome<|>8)\n##\n(\"relationship\"<|>BILLER BMK<|>UPTODATE INC<|>Biller BMK has contributed to the UpToDate Inc. literature reviews on Cushing's syndrome<|>8)\n##\n(\"relationship\"<|>FINDILING JW<|>UPTODATE INC<|>Findiling JW has contributed to the UpToDate Inc. literature reviews on Cushing's syndrome<|>8)\n##\n(\"relationship\"<|>NEWEL-PRICE J<|>UPTODATE INC<|>Newel-Price J has contributed to the UpToDate Inc. literature reviews on Cushing's syndrome<|>8)\n##\n(\"relationship\"<|>SAVAGE MO<|...|>UPTODATE INC<|>Savage MO has contributed to the UpToDate Inc. literature reviews on Cushing's syndrome<|>8)\n##\n(\"relationship\"<|>STEWARD PM<|>UPTODATE INC<|>Steward PM has contributed to the UpToDate Inc. literature reviews on Cushing's syndrome<|>8)\n##\n(\"relationship\"<|>NIEMAN LK<|>HARRISON SOCIETY<|>Nieman LK has contributed to the Harrison Society's clinical practice guidelines on Cushing's syndrome<|>8)\n##\n(\"relationship\"<|>BILLER BMK<|>HARRISON SOCIETY<|>Biller BMK has contributed to the Harrison Society's clinical practice guidelines on Cushing's syndrome<|>8)\n##\n(\"relationship\"<|>FINDILING JW<|>HARRISON SOCIETY<|>Findiling JW has contributed to the Harrison Society's clinical practice guidelines on Cushing's syndrome<|>8)\n##\n(\"relationship\"<|>NEWEL-PRICE J<|>HARRISON SOCIETY<|>Newel-Price J has contributed to the Harrison Society's clinical practice guidelines on Cushing's syndrome<|>8)\n##\n(\"relationship\"<|>SAVAGE MO<|>HARRISON SOCIETY<|>Savage MO has contributed to the Harrison Society's clinical practice guidelines on Cushing's syndrome<|>8)\n##\n(\"relationship\"<|>STEWARD PM<|>HARRISON SOCIETY<|>Steward PM has contributed to the Harrison Society's clinical practice guidelines on Cushing's syndrome<|>8)\n##\n(\"relationship\"<|>CUSHING'S SYNDROME<|>CLINICAL PRACTICE GUIDELINE<|>Cushing's syndrome is the subject of various clinical practice guidelines developed by medical professionals<|>10)\n<|COMPLETE|>"}]}